Cancer

Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1, the GLS inhibitor CB-839 plus radiation or CB-839 plus ROS-inducing tert-butylhydroperoxide decreased survival compared with vehicle plus radiation or vehicle plus tert-butylhydroperoxide. In an orthotopic xenograft mouse model of IDH1-mutant glioma, CB-839 plus radiation decreased tumor growth and increased survival compared with either treatment alone. Next steps could include testing CB-839 plus radiation in other models of IDH1-mutant glioma...